Electrophysiologic effects of carvedilol: Is carvedilol an antiarrhythmic agent?

被引:27
作者
El-Sherif, N
Turitto, G
机构
[1] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA
[2] NY Harbor VA Healthcare Ctr, Brooklyn, NY USA
[3] New York Methodist Hosp, Brooklyn, NY USA
来源
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY | 2005年 / 28卷 / 09期
关键词
arrhythmias; carvedilol; electrophysiology;
D O I
10.1111/j.1540-8159.2005.00200.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Electrophysiologic Effects of Carvedilol: Is Carvedilol an Antiarrhythmic Agent? The cardiovascular drug carvedilol is characterized by multiple pharmacological actions, which translate into a wide-spectrum therapeutic potential. Its major molecular targets are membrane adrenoceptors, ion channels, and reactive oxygen species. Carvedilol's favorable hemodynamic effects are due to the fact that the drug competitively blocks beta(1), beta(2)-, and alpha(1)-adrenoceptors. Several additional properties have been documented and may be clinically important, including antioxidant, antiproliferative/antiatherogenic, anti-ischemic, and antihypertrophic effects. The antiarrhythmic action of carvedilol may be related to a combination of its beta-blocking effects with its modulating effects on a variety of ion channels and currents. Several studies suggest that the drug may be useful in reducing cardiac death in high-risk patients with prior myocardial infarction and/or heart failure, as well as for primary and secondary prevention of atrial fibrillation. This article will review experimental data available on the electrophysiologic properties of carvedilol, with a focus on their clinical relevance.
引用
收藏
页码:985 / 990
页数:6
相关论文
共 50 条
[1]   b-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts [J].
Asanuma, H ;
Minamino, T ;
Sanada, S ;
Takashima, S ;
Ogita, H ;
Ogai, A ;
Asakura, M ;
Liao, YL ;
Asano, Y ;
Shintani, Y ;
Kim, J ;
Shinozaki, Y ;
Mori, H ;
Node, K ;
Kitamura, S ;
Tomoike, H ;
Hori, M ;
Kitakaze, M .
CIRCULATION, 2004, 109 (22) :2773-2779
[2]   QT DISPERSION AND SUDDEN UNEXPECTED DEATH IN CHRONIC HEART-FAILURE [J].
BARR, CS ;
NAAS, A ;
FREEMAN, M ;
LANG, CC ;
STRUTHERS, AD .
LANCET, 1994, 343 (8893) :327-329
[3]   Ionic mechanisms of electrical remodeling in human atrial fibrillation [J].
Bosch, RF ;
Zeng, XR ;
Grammer, JB ;
Popovic, K ;
Mewis, C ;
Kühlkamp, V .
CARDIOVASCULAR RESEARCH, 1999, 44 (01) :121-131
[4]   Molecular mechanisms of remodeling in human atrial fibrillation [J].
Brundel, BJJM ;
Henning, RH ;
Kampinga, HH ;
Van Gelder, IC ;
Crijns, HJGM .
CARDIOVASCULAR RESEARCH, 2002, 54 (02) :315-324
[5]  
Brundel BJJM, 2001, CIRCULATION, V103, P684
[6]   Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury [J].
Brunvand, H ;
Froyland, L ;
Hexeberg, E ;
Rynning, SE ;
Berge, RK ;
Grong, K .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 314 (1-2) :99-107
[7]   Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation [J].
Carnes, CA ;
Chung, MK ;
Nakayama, T ;
Nakayama, H ;
Baliga, RS ;
Piao, S ;
Kanderian, A ;
Pavia, S ;
Hamlin, RL ;
McCarthy, PM ;
Bauer, JA ;
Van Wagoner, DR .
CIRCULATION RESEARCH, 2001, 89 (06) :E32-E38
[8]  
Cheng JH, 2001, CARDIOVASC DRUG REV, V19, P152
[9]   Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes [J].
Cheng, JH ;
Niwa, R ;
Kamiya, K ;
Toyama, J ;
Kodama, I .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 376 (1-2) :189-201
[10]   C-reactive protein elevation in patients with atrial arrhythmias - Inflammatory mechanisms and persistence of atrial fibrillation [J].
Chung, MK ;
Martin, DO ;
Sprecher, D ;
Wazni, O ;
Kanderian, A ;
Carnes, CA ;
Bauer, JA ;
Tchou, PJ ;
Niebauer, MJ ;
Natale, A ;
Van Wagoner, DR .
CIRCULATION, 2001, 104 (24) :2886-2891